Physician profile
Linus A Wodi
NPI 1841242906
$2,601.12
in general payments reported to CMS, 2019-2025
15 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.48 · 2022: $415 · 2023: $985 · 2024: $642 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $1,270.49 | 2022-2025 | Assure Wcd |
| Biotronik INC. | $306.26 | 2022 | |
| Cvrx, INC. | $206.75 | 2022-2025 | Barostim Neo System |
| Medtronic, INC. | $195.66 | 2024 | Corevalve Evolut R |
| Boston Scientific Corporation | $189.70 | 2023 | Watchman Access System, Ekosonic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.54 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $100.70 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $37.85 | 2023 | Verquvo |
| Pfizer INC. | $35.53 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $21.59 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $21.34 | 2024 | Camzyos |
| Amgen INC. | $19.42 | 2022 | |
| Abbott Laboratories | $17.31 | 2023 | Cardiomems |
| Resmed Corp | $17.18 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.80 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linus Wodi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.